Recurrent Pancreatic Carcinoma Completed Phase 1 Trials for Pembrolizumab (DB09037)

Also known as: Pancreatic carcinoma recurrent / Pancreas carcinoma recurrent / Pancreatic cancer recurrent

IndicationStatusPhase
DBCOND0043478 (Recurrent Pancreatic Carcinoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03095781Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal CancerTreatment